메뉴 건너뛰기




Volumn 74, Issue 3, 2015, Pages 538-546

Golimumab 3-year safety update: An analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GOLIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

EID: 84922341068     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204195     Document Type: Article
Times cited : (76)

References (48)
  • 1
    • 85028154920 scopus 로고    scopus 로고
    • Abbott Laboratories, Last revised September 2012. (accessed 17 Apr 2013)
    • Abbott Laboratories. Humira (adalimumab) [highlights of prescribing information]. Last revised September 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125057s232lbl.pdf (accessed 17 Apr 2013).
    • Humira (Adalimumab) [Highlights of Prescribing Information]
  • 2
    • 85028150936 scopus 로고    scopus 로고
    • UCB Inc., Last revised November 2012, (accessed 17 Apr 2013)
    • UCB Inc. Cimzia (certolizumab) [highlights of prescribing information]. Last revised November 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125160s189lbl.pdf (accessed 17 Apr 2013).
    • Cimzia (Certolizumab) [Highlights of Prescribing Information]
  • 3
    • 85028156216 scopus 로고    scopus 로고
    • Amgen Wyeth manufactured by Immunex, Last revised December 2012, (accessed 17 Apr 2013)
    • Amgen Wyeth, manufactured by Immunex. Enbrel (etanercept) [highlights of prescribing information]. Last revised December 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/103795s5507lbl.pdf (accessed 17 Apr 2013).
    • Enbrel (Etanercept) [Highlights of Prescribing Information]
  • 4
    • 85028150936 scopus 로고    scopus 로고
    • Janssen Biotech, Inc., Last revised March 2013, (accessed 17 Apr 2013)
    • Janssen Biotech, Inc. Remicade (infliximab) [highlights of prescribing information]. Last revised March 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103772s5345lbl.pdf (accessed 17 Apr 2013).
    • Remicade (Infliximab) [Highlights of Prescribing Information]
  • 5
    • 85028150936 scopus 로고    scopus 로고
    • Janssen Biotech, Inc., Last revised November 2012, (accessed 17 Apr 2013)
    • Janssen Biotech, Inc. Simponi (golimumab) [highlights of prescribing information]. Last revised November 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125289s070lbl.pdf (accessed 17 Apr 2013).
    • Simponi (Golimumab) [Highlights of Prescribing Information]
  • 6
    • 79953018875 scopus 로고    scopus 로고
    • Adverse effects of biologics: A network meta-analysis and Cochrane overview
    • Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2: CD008794.
    • (2011) Cochrane Database Syst Rev , vol.2 , pp. CD008794
    • Singh, J.A.1    Wells, G.A.2    Christensen, R.3
  • 7
    • 78649645500 scopus 로고    scopus 로고
    • Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
    • Kay J, Rahman MU. Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 2010;4:159-70.
    • (2010) Core Evid , vol.4 , pp. 159-170
    • Kay, J.1    Rahman, M.U.2
  • 8
    • 42449157502 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
    • Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
    • (2008) Arthritis Rheum , vol.58 , pp. 964-975
    • Kay, J.1    Matteson, E.L.2    Dasgupta, B.3
  • 9
    • 68049099274 scopus 로고    scopus 로고
    • Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
    • Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
    • (2009) Arthritis Rheum , vol.60 , pp. 2272-2283
    • Emery, P.1    Fleischmann, R.M.2    Moreland, L.W.3
  • 10
    • 84887089482 scopus 로고    scopus 로고
    • Golimumab, a human anti-TNF monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naïve patients with active rheumatoid arthritis: 1-year and 2-year clinical, radiological, and physical function findings of a Phase 3, multicenter, randomized, double-blind, placebo-controlled study
    • Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-TNF monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naïve patients with active rheumatoid arthritis: 1-year and 2-year clinical, radiological, and physical function findings of a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken) 2013;65:1732-1742.
    • (2013) Arthritis Care Res (Hoboken) , vol.65 , pp. 1732-1742
    • Emery, P.1    Fleischmann, R.M.2    Doyle, M.K.3
  • 11
    • 67449133560 scopus 로고    scopus 로고
    • Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study
    • Keystone E, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
    • (2009) Ann Rheum Dis , vol.68 , pp. 789-796
    • Keystone, E.1    Genovese, M.C.2    Klareskog, L.3
  • 12
    • 77953701867 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
    • Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1129-1135
    • Keystone, E.1    Genovese, M.C.2    Klareskog, L.3
  • 13
    • 84879891418 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Results through 2 years of the GO-FORWARD study extension
    • Keystone E, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 2013;40:1097-1103.
    • (2013) J Rheumatol , vol.40 , pp. 1097-1103
    • Keystone, E.1    Genovese, M.C.2    Hall, S.3
  • 14
    • 67650379733 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
    • Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
    • (2009) Lancet , vol.374 , pp. 210-221
    • Smolen, J.S.1    Kay, J.2    Doyle, M.K.3
  • 15
    • 84866104476 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: Results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
    • Smolen JS, Kay J, Landewé RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71:1671-9.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1671-1679
    • Smolen, J.S.1    Kay, J.2    Landewé, R.B.3
  • 16
    • 65249137637 scopus 로고    scopus 로고
    • Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
    • Kavanaugh A, McInnes IB, Mease PJ, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
    • (2009) Arthritis Rheum , vol.60 , pp. 976-986
    • Kavanaugh, A.1    McInnes, I.B.2    Mease, P.J.3
  • 17
    • 84864438913 scopus 로고    scopus 로고
    • Golimumab in psoriatic arthritis: One year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    • Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
    • (2012) Arthritis Rheum , vol.64 , pp. 2504-2517
    • Kavanaugh, A.1    Van Der Heijde, D.2    McInnes, I.B.3
  • 18
    • 84885181527 scopus 로고    scopus 로고
    • Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
    • Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-1785.
    • (2013) Ann Rheum Dis , vol.72 , pp. 1777-1785
    • Kavanaugh, A.1    McInnes, I.B.2    Mease, P.J.3
  • 19
    • 55849108826 scopus 로고    scopus 로고
    • Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
    • Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
    • (2008) Arthritis Rheum , vol.58 , pp. 3402-3412
    • Inman, R.D.1    Davis, J.C.2    Van Der Heijde, D.3
  • 20
    • 84859509505 scopus 로고    scopus 로고
    • Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
    • Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012;71:661-7.
    • (2012) Ann Rheum Dis , vol.71 , pp. 661-667
    • Braun, J.1    Deodhar, A.2    Inman, R.D.3
  • 21
    • 0029044362 scopus 로고
    • American College of Rheumatology: Preliminary definition of improvement in rheumatoid arthritis
    • Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
    • (1995) Arthritis Rheum , vol.38 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3
  • 22
    • 0021272107 scopus 로고
    • Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
    • van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
    • (1984) Arthritis Rheum , vol.27 , pp. 361-368
    • Van Der Linden, S.1    Valkenburg, H.A.2    Cats, A.3
  • 23
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
    • Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
    • (1994) J Rheumatol , vol.21 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3
  • 24
    • 84862964714 scopus 로고    scopus 로고
    • Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: An open-label, randomized study
    • Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012;34:77-90.
    • (2012) Clin Ther , vol.34 , pp. 77-90
    • Zhuang, Y.1    Xu, Z.2    Frederick, B.3
  • 25
    • 64549145652 scopus 로고    scopus 로고
    • National Cancer Institute: Surveillance Epidemiology and End Results, (accessed 17 Apr 2013)
    • National Cancer Institute: Surveillance, Epidemiology, and End Results. Overview of the SEER program. http://SEER.cancer.gov/about/overview.html (accessed 17 Apr 2013).
    • Overview of the SEER Program
  • 26
    • 84863871272 scopus 로고    scopus 로고
    • Assessing the safety of biologic agents in patients with rheumatoid arthritis
    • Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51:v38-47.
    • (2012) Rheumatology (Oxford) , vol.51 , pp. v38-v47
    • Rubbert-Roth, A.1
  • 27
    • 84874445437 scopus 로고    scopus 로고
    • Adalimumab: Long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
    • Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
    • (2013) Ann Rheum Dis , vol.72 , pp. 517-524
    • Burmester, G.R.1    Panaccione, R.2    Gordon, K.B.3
  • 28
    • 34848816866 scopus 로고    scopus 로고
    • Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
    • Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1339-1344
    • Askling, J.1    Fored, C.M.2    Brandt, L.3
  • 29
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
    • (2006) JAMA , vol.295 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3
  • 30
    • 34247218183 scopus 로고    scopus 로고
    • Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
    • Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
    • (2007) Arthritis Rheum , vol.56 , pp. 1125-1133
    • Curtis, J.R.1    Patkar, N.2    Xie, A.3
  • 31
    • 79951712039 scopus 로고    scopus 로고
    • Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
    • on behalf of the British Society for Rheumatology Biologics Register Control Centre Consortium
    • Galloway JB, Hyrich KL, Mercer LK, et al.; on behalf of the British Society for Rheumatology Biologics Register Control Centre Consortium. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 124-131
    • Galloway, J.B.1    Hyrich, K.L.2    Mercer, L.K.3
  • 32
    • 78049494652 scopus 로고    scopus 로고
    • Initiation of rheumatoid arthritis treatments and the risk of serious infections
    • Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010;49: 82-90.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 82-90
    • Grijalva, C.G.1    Kaltenbach, L.2    Arbogast, P.G.3
  • 33
    • 27744458586 scopus 로고    scopus 로고
    • Infections in patients with rheumatoid arthritis treated with biologic agents
    • Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
    • (2005) Arthritis Rheum , vol.52 , pp. 3403-3412
    • Listing, J.1    Strangfeld, A.2    Kary, S.3
  • 34
    • 60749125474 scopus 로고    scopus 로고
    • Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
    • Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
    • (2009) JAMA , vol.301 , pp. 737-744
    • Strangfeld, A.1    Listing, J.2    Herzer, P.3
  • 35
    • 67549117204 scopus 로고    scopus 로고
    • The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events
    • Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1136-1145
    • Leombruno, J.P.1    Einarson, T.R.2    Keystone, E.C.3
  • 36
    • 66449083072 scopus 로고    scopus 로고
    • Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans
    • Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-77.
    • (2009) J Clin Invest , vol.119 , pp. 1167-1177
    • Bruns, H.1    Meinken, C.2    Schauenberg, P.3
  • 37
    • 84873197989 scopus 로고    scopus 로고
    • Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials
    • Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials. Arthritis Care Res (Hoboken) 2013;65:309-13.
    • (2013) Arthritis Care Res (Hoboken) , vol.65 , pp. 309-313
    • Hsia, E.C.1    Cush, J.J.2    Matteson, E.L.3
  • 38
    • 84863217872 scopus 로고    scopus 로고
    • Interferon-? Release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
    • Hsia EC, Schluger N, Cush JJ, et al. Interferon-? release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-77.
    • (2012) Arthritis Rheum , vol.64 , pp. 2068-2077
    • Hsia, E.C.1    Schluger, N.2    Cush, J.J.3
  • 39
    • 84868135421 scopus 로고    scopus 로고
    • Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: Drug-specific comparisons in the Swedish Biologics Register
    • Simard JF, Neovius M, Askling J; for the ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 2012;64:3502-10.
    • (2012) Arthritis Rheum , vol.64 , pp. 3502-3510
    • Simard, J.F.1    Neovius, M.2    Askling, J.3
  • 40
    • 34248185611 scopus 로고    scopus 로고
    • Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
    • Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5.
    • (2007) Ann Rheum Dis , vol.66 , pp. 670-675
    • Jacobsson, L.T.1    Turesson, C.2    Nilsson, J.A.3
  • 41
    • 79961111305 scopus 로고    scopus 로고
    • Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: A review of long-term data
    • Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of long-term data. J Rheumatol 2011;38:1552-62.
    • (2011) J Rheumatol , vol.38 , pp. 1552-1562
    • Keystone, E.C.1
  • 42
    • 80053565309 scopus 로고    scopus 로고
    • Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis
    • Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1895-1904
    • Mariette, X.1    Matucci-Cerinic, M.2    Pavelka, K.3
  • 43
    • 84865692521 scopus 로고    scopus 로고
    • Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis
    • Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA. et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
    • (2012) JAMA , vol.308 , pp. 898-908
    • Lopez-Olivo, M.A.1    Tayar, J.H.2    Martinez-Lopez, J.A.3
  • 44
    • 33644892763 scopus 로고    scopus 로고
    • Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
    • Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
    • (2006) Arthritis Rheum , vol.54 , pp. 692-701
    • Baecklund, E.1    Iliadou, A.2    Askling, J.3
  • 45
    • 34248547187 scopus 로고    scopus 로고
    • The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation
    • Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
    • (2007) Arthritis Rheum , vol.56 , pp. 1433-1439
    • Wolfe, F.1    Michaud, K.2
  • 46
    • 78751685797 scopus 로고    scopus 로고
    • Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
    • Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30.
    • (2011) Pharmacoepidemiol Drug Saf , vol.20 , pp. 119-130
    • Askling, J.1    Fahrbach, K.2    Nordstrom, B.3
  • 47
    • 77956021184 scopus 로고    scopus 로고
    • Demyelinating events in rheumatoid arthritis after drug exposures
    • Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010;69:1691-3.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1691-1693
    • Bernatsky, S.1    Renoux, C.2    Suissa, S.3
  • 48
    • 78751704873 scopus 로고    scopus 로고
    • Demyelinating disease in patients treated with TNF antagonists in rheumatology: Data from BIOBADASER, a pharmacovigilance database, and a systematic review
    • Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011;40:330-7.
    • (2011) Semin Arthritis Rheum , vol.40 , pp. 330-337
    • Fernández-Espartero, M.C.1    Pérez-Zafrilla, B.2    Naranjo, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.